University of Chicago Medicine
Comprehensive Cancer Center
Chicago, IL
Accepting patients
QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
EXCALIBER - Maintenance
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3